Ghent, Belgium – June 2, 2020
Funding will support product range extension of micro-chip based µPAC™ nano, capillary and microflow LC columns, and accelerated development of manufacturing process know-how.
PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO).
The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
“The funding will allow us to build proprietary process know-how and allow PharmaFluidics to further advance the reproducibility and reliability of our micro-chip based µPAC™ nano, capillary and micro-LC columns, which are already amongst their distinguishing features” Paul Jacobs, PharmaFluidics’ COO commented. “We are grateful to VLAIO for recognizing PharmaFluidics’ innovations and providing support for the further development of its process know-how and product portfolio”, added Johan Devenyns, CEO.
PharmaFluidics develops and commercializes its unique μPACᵀᴹ range of micro-chip based chromatography columns for use in biomarker, diagnostics and drug research & development applications in the global biotech and pharma industries. The unprecedented, game-changing separation performance of PharmaFluidics’ μPACᵀᴹ chromatography columns allows to identify substantially more compounds in complex biological samples, such as biopsies, proteome digests, culture media or bio-pharmaceutical actives.
The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence and pioneer users to develop an increasing range of applications.
+ 32 9 241 56 10